15.12.2020 WDR Bergische Forschung für Corona

AiCuris receives approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

Approval from the German “Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)” to initiate a Compassionate Use Program (Härtefallprogramm) for pritelivir.

more ...


Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente

„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“

more ...


Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

more ...


AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference

AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”

more ...


Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (Letermovir) from AiCuris

Royalty Pharma and AiCuris have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time-payment of $220 million.

more ...


AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

AiCuris has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV)

more ...


AiCuris unterstützt das Land NRW bei der COVID-19 Ausbruchsbekämpfung in Schlachtbetrieben
An der Durchführung der ca. 20.000 Testung beteiligt sich AiCuris neben den vier Chemischen und Veterinäruntersuchungsämter des Landes.

more ...


AiCuris gets involved in the fight against Corona

“In times like these, biotech and pharmaceutical companies have a great societal responsibility”

more ...


AiCuris collaborates with myTomorrows to initiate an Early Access Program for Pritelivir

AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

more ...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:

Katja Woestenhemke
Management Assistant

AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)aicuris.com